Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Goldman Sachs 45th Annual Global Healthcare Conference June 11, 2024 11:20 AM ET Company Participants David Altshuler - Chief Scientific Officer Charles Wagner - CFO Conference Call Participants Salveen Richter - Goldman Sachs Salveen Richter Great. Good morning, everyone. Thank you so much for joining us. Really pleased to have the Vertex team here with us. Today, we do have David Altshuler, Chief Scientific Officer; as well as Charlie Wagner, CFO. Question ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) The 44th Annual William Blair Growth Stock Conference June 4, 2024 5:00 PM ET Company Participants Reshma Kewalramani - Chief Executive Officer Conference Call Participants Myles Minter - William Blair Sami Corwin - William Blair Myles Minter All right, thank you very much. Welcome back to the William Blair Growth Stock Conference, the 44th Edition, as I understand it. My name is Myles Minter. I'm a Senior Biotech analyst here at the firm. I'm joined next to ...

It has been about a month since the last earnings report for Vertex Pharmaceuticals (VRTX) . Shares have added about 15.8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Vertex due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Q1 Earnings Beat, Trikafta Drives Sales ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. Zacks Premium also includes the Zacks Style Score ...

Earnings Estimate Revisions Rather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings. Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past month, shares of this ...

Vertex Pharmaceuticals Incorporated (VRTX) has been benefiting from strong revenue growth, regulatory approvals and commercial launches in the past year. Vertex enjoys a dominant position in the cystic fibrosis (CF) market. Vertex's CF sales continue to grow, driven by its triple therapy, Trikafta (marketed as Kaftrio in Europe). In the United States, Trikafta sales are being fueled by label expansions to younger age groups (two to five years old). In the ex-U.S. markets, the drug continues to witness stron ...

Vertex Pharmaceuticals (NDAQ: VRTX) stands today as a top 20 pharma company with over a $100 billion market cap. But this biotech beacon has ridden a bumpy path to its current perch and, along the way, just may have authored a new playbook for life sciences R&D. Founded in 1989, Vertex's rollercoaster story is most iconically characterized by the rise and fall of Incivek, a hepatitis C drug that reached $1 billion in sales faster than any before it, only to be withdrawn from the market just three years afte ...

The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Z ...

The biotech's shares dropped following its latest quarterly update, but that shouldn't matter to long-term investors.There are several textbook arguments against monopolies. According to one of them, companies that control a market can lower the quality of their products with impunity.However, Vertex Pharmaceuticals (VRTX 0.91%), a drugmaker with a monopoly in the cystic fibrosis (CF) market, hasn't done that -- quite the contrary. Since it launched its first CF product some 12 years ago, the biotech hasn't ...

For the quarter ended March 2024, Vertex Pharmaceuticals (VRTX) reported revenue of $2.69 billion, up 13.3% over the same period last year. EPS came in at $4.76, compared to $3.05 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $2.56 billion, representing a surprise of +5.15%. The company delivered an EPS surprise of +16.10%, with the consensus EPS estimate being $4.10.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- ...